Abstract
The ESMO Guidelines Committee would like to publish a correction to Table S6 in the Supplementary data file originally published in 2020. The authors have added a cautionary comment to a specific dosing recommendation for first-line treatment in newly diagnosed AML patients. 1. Induction and consolidation ChT for patients with CBF-AML, Induction 2 The following text is added: “The doses of cytarabine and daunorubicin recommended here differ from the licensed doses described in the licensing information of GO. Some study groups reduce the dose of daunorubicin or the number of treatment days of daunorubicin.” 4. Standard induction and consolidation ChT with or without GO for patients with ELN favourable (ELN1) or intermediate (ELN2) risk AML, Induction 2 The following text is added: “If GO was used in induction cycle 1: The doses of cytarabine and daunorubicin recommended here differ from the licensed doses described in the licensing information of GO. Some study groups reduce the dose of daunorubicin or the number of treatment days of daunorubicin.”
Original language | English |
---|---|
Pages (from-to) | 821 |
Number of pages | 1 |
Journal | Annals of Oncology |
Volume | 32 |
Issue number | 6 |
DOIs |
|
Publication status | Published - 1 Jun 2021 |